Rafferty Asset Management LLC Lowers Position in Danaher Corporation $DHR

Key Points

• Rafferty Asset Management LLC reduced its holdings in Danaher Corporation by 18.7%, owning 59,257 shares worth approximately $12.15 million post-sale.
• Analysts have set a consensus price target of $247.61 for Danaher, with remarks from firms like Guggenheim and Scotiabank reaffirming buy ratings.
• Danaher reported $5.94 billion in revenue for the latest quarter, beating estimates, alongside a quarterly EPS of $1.80 which surpassed expectations by $0.16.

Rafferty Asset Management LLC cut its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 18.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,257 shares of the conglomerate's stock after selling 13,647 shares during the quarter. Rafferty Asset Management LLC's holdings in Danaher were worth $12,148,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Findlay Park Partners LLP lifted its holdings in Danaher by 37.6% during the 1st quarter. Findlay Park Partners LLP now owns 584,800 shares of the conglomerate's stock worth $119,884,000 after buying an additional 159,800 shares during the period. Ceredex Value Advisors LLC lifted its holdings in Danaher by 10.1% during the 1st quarter. Ceredex Value Advisors LLC now owns 245,515 shares of the conglomerate's stock worth $50,331,000 after buying an additional 22,442 shares during the period. FORA Capital LLC lifted its holdings in Danaher by 108.1% during the 1st quarter. FORA Capital LLC now owns 16,847 shares of the conglomerate's stock worth $3,454,000 after buying an additional 8,750 shares during the period. Harvest Portfolios Group Inc. lifted its holdings in Danaher by 9.8% during the 1st quarter. Harvest Portfolios Group Inc. now owns 248,049 shares of the conglomerate's stock worth $50,850,000 after buying an additional 22,200 shares during the period. Finally, South Plains Financial Inc. lifted its holdings in Danaher by 39.7% during the 1st quarter. South Plains Financial Inc. now owns 848 shares of the conglomerate's stock worth $174,000 after buying an additional 241 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is owned by insiders.

Danaher Stock Performance

Danaher stock traded down $4.81 during trading on Tuesday, hitting $201.01. The stock had a trading volume of 781,550 shares, compared to its average volume of 4,150,984. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock's 50 day moving average is $201.84 and its two-hundred day moving average is $199.46. The stock has a market cap of $143.93 billion, a price-to-earnings ratio of 42.73, a price-to-earnings-growth ratio of 2.87 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period last year, the company earned $1.72 earnings per share. The business's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on DHR shares. Deutsche Bank Aktiengesellschaft cut their target price on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wells Fargo & Company lowered their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Evercore ISI lowered their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Finally, Robert W. Baird boosted their price objective on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a report on Friday, July 18th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.